Chief Science Officer, Head of Global Discovery, Early Development & CMC Teva Pharmaceuticals West Chester, Pennsylvania
Cancer immunotherapy has introduced a revolutionary paradigm. In this presentation, we will first explore the potential of checkpoint inhibitors and highlight ongoing research efforts unveiling novel modalities for cancer immunotherapy. Additionally, we will systematically review the challenges associated with developing these new modalities, including hurdles in developability, concerns regarding formulation and complexities of manufacturing. A strategic overview will be provided, offering insights into navigating the challenges from discovery and development through to clinical applications. By integrating advanced scientific insights with strategic development tactics, the future of cancer immunotherapy shines brightly, offering hope to the millions confronted by this daunting disease.
Learning Objectives:
Discuss the potential of checkpoint inhibitors and highlight ongoing research efforts unveiling novel modalities for cancer immunotherapy
Understand the challenges associated with developing new modalities
Undestand hurdles in developability, concerns regarding formulation stability and complexities of manufacturing
